Cephalon Boosts Cancer Pipeline With Acquisition Valued At Up to $525 Million
This article was originally published in The Pink Sheet Daily
Executive Summary
The specialty biopharma has gained two promising oncology drugs through the acquisition of privately-held Gemin X